AbbVie to acquire Apogee Therapeutics in $10.9B deal

Abbvie Inc (NYSE:ABBV) announced that it volition get Apogee Therapeutics (NASDAQ:APGE) successful an all-cash transaction valued astatine astir $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma.

Under the presumption of the definitive statement announced Sunday, AbbVie volition get each outstanding Apogee shares for $135.11 per stock successful cash.

The boards of directors of some companies unanimously approved the deal, which is expected to adjacent successful the 3rd 4th of 2026, taxable to customary closing conditions, including regulatory clearances and support by Apogee shareholders.

The acquisition volition bring respective clinical-stage candidates into AbbVie's immunology portfolio. Apogee's pb asset, zumilokibart (APG777), is simply a half-life extended monoclonal antibody targeting interleukin-13 (IL-13) that is being developed for atopic dermatitis.

The institution said Phase 2 results showed astir two-thirds of treated patients achieved important tegument clearance aft 16 weeks, with improvements successful itch simplification and illness control. Longer-term information besides supported quarterly oregon twice-yearly attraction dosing.

Apogee is besides processing APG273, a operation therapy consisting of zumilokibart and APG333, an anti-TSLP antibody, for asthma. Phase 1 information indicated APG333 maintained suppression of benignant 2 inflammatory markers for up to six months aft dosing.

AbbVie said the acquisition complements its existing immunology concern and is expected to fortify its beingness successful respiratory diseases.

The institution expects the transaction to beryllium accretive to adjusted diluted net per stock opening successful 2032.

Shares of AbbVie added 4.5% astatine $226 connected the news, portion Apogee shares surged 47% to astir $133.